First quarter performance update

Blis Technologies Limited: Ground Floor, 442 Moray Place, Dunedin Central 9016, PO Box 2208, Dunedin 9044, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz





21 July 2023

First quarter performance update

Blis Technologies Limited (Blis) delivers revenue growth of 18% and a break-even EBITDA result for
the first quarter ending 30 June 2023 (unaudited).

Revenue for the three months to 30 June 2023 was $2.8m, an increase of $0.4m compared with the
same period last year. EBITDA was breakeven $0.0m compared with a loss of $0.3m in the same
period last year.

“Following a profitable second half of FY23, we are pleased to start the year with a break-even
quarter in line with our expectations. The first quarter revenue growth is from our B2B business,
with an increase in Probi royalties and a lift in US ingredient sales for the quarter. Our B2C revenue
for the quarter was similar to the same period last year.”

“We continue to see the refreshed strategy and business model drive revenue growth and support
our journey back to profitability.” said Brian Watson CEO.

Ends

For further information, please contact:

Brian Watson
CEO
+64 27 705 9133


About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout New Zealand
and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics